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Purpose: Folate is essential to DNA methylation and synthesis and may have a
complex dualistic role in prostate cancer. Alcohol use may increase risk and epigenetic
factors may interact with lifestyle exposures. We aimed to characterize the independent
and joint effects of folate intake, alcohol consumption, and the MTHFR C677T gene
polymorphism on prostate cancer risk, while accounting for intakes of vitamins B2, B6,
B12, methionine, total energy, and confounders. Methods: A case-control study was
conducted at Kingston General Hospital of 80 incident primary prostate cancer cases
and 334 urology clinic controls, all with normal age-specific PSA levels (to exclude
latent prostate cancers). Participants completed a questionnaire on folate and alcohol
intakes and potential confounders prior to knowledge of diagnosis, eliminating recall
bias, and blood was drawn for MTHFR genotyping. Joint effects of exposures were
assessed using unconditional logistic regression and significance of multiplicative and
additive interactions using general linear models. Results: Folate, vitamins B2, B6,
B12, methionine, and the CT and TT genotypes were not associated with prostate
cancer risk. The highest tertile of lifetime alcohol consumption was associated with
increased risk (OR = 2.08; 95% CI: 1.12–3.86). Consumption of >5 alcoholic drinks
per week was associated with increased prostate cancer risk among men with low
folate intake (OR = 2.38; 95% CI: 1.01–5.57), and higher risk among those with the CC
MTHFR genotype (OR = 4.43; 95% CI: 1.15–17.05). Increased risk was also apparent for
average weekly alcohol consumption when accounting for the multiplicative interaction
between folate intake and MTHFR C677T genotype (OR = 3.22; 95% CI: 1.36–7.59).
Conclusion: Alcohol consumption is associated with increased prostate cancer risk, and
this association is stronger among men with low folate intake, with the CC MTHFR
genotype, and when accounting for the joint effect of folate intake and MTHFR C677T
genotype.
Keywords: prostate cancer, folate, alcohol, genetic variants, carbon metabolism, gene-environment interactions,
case-control study, male health
INTRODUCTION
Prostate cancer is the second most common malignancy among
men (Ferlay et al., 2010). With 5–10% attributable to family his-
tory and genetic susceptibility (National Cancer Institute, 2004),
etiology of prostate cancer is largely unknown (International
Agency for Research on Cancer, 2008). One dietary factor with
a complex relationship with prostate cancer is folate, a water-
soluble B vitamin that provides substrates for DNA methylation
and synthesis of purines and thymidine (Kim, 1999; Fairfield
and Fletcher, 2002). Biologic plausibility exists for the contri-
bution of both high and low folate intakes to prostate car-
cinogenesis. Deficient folate levels have been shown in murine
prostate cancer models to result in CpG island hypermethyla-
tion and misincorporation of uracil into DNA strands, leading
to genetic and epigenetic instability that is characteristic of car-
cinogenesis (Bistulfi et al., 2010). Conversely, folate deficiency
can halt progression of pre-existing tumors in the murine model
(Tomaszewski et al., 2011) and high serum folate concentra-
tions have been associated with an increased rate of progression
among men with existing prostate cancer (Collin et al., 2010a).
Conflicting results from epidemiological research may reflect
this potential dualistic role of folate in prostate carcinogene-
sis (Vlajinac et al., 1997; Weinstein et al., 2003; Hultdin et al.,
2005; Pelucchi et al., 2005; Rossi et al., 2006; Stevens et al., 2006;
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Johansson et al., 2008; Figueiredo et al., 2009; Shannon et al.,
2009; Zhang et al., 2009; Beilby et al., 2010; Collin et al., 2010a,b).
Understanding of the true effects of folate intake on prostate
carcinogenesis is warranted to inform dietary recommendations,
especially in the context where many countries have implemented
fortification of several foods with folate (Lucock and Yates, 2009).
The effects of folate may be moderated by two potential inde-
pendent risk factors for prostate cancer: alcohol consumption,
and the C677T polymorphism of the methylenetetrahydrofo-
late reductase (MTHFR) gene. A meta-analysis in 2009 showed
that consistently heavy alcohol drinking confers higher risk for
prostate cancer (Middleton Fillmore et al., 2009). Alcohol directly
interferes with the actions of folate in the body by inhibiting
its absorption in the small intestine (Dennis, 2000). Heavier
drinkers thus have a greater need for folate, which may place
them at higher risk for prostate cancer. While some previ-
ous epidemiological studies on prostate cancer have controlled
for alcohol as a confounding factor, only four have assessed
an interaction between folate intake and alcohol consumption,
and these have had yielded conflicting results (Weinstein et al.,
2003; Pelucchi et al., 2005; Stevens et al., 2006; Shannon et al.,
2009).
The MTHFR gene encodes the MTHFR enzyme that plays
an essential role in folate metabolism by catalyzing the produc-
tion of 5-methyltetrahydrofolate, the main circulating form of
folate required for DNA methylation (Lathrop Stern et al., 2000).
The C677T (cytosine-to-thymine) mutation of theMTHFR gene,
CC in wildtype, can produce the heterozygous CT gene variant
or the homozygous TT variant: the CT variant occurs in 50%
of the population and results in 65% of the wildtype enzyme’s
functional activity, while the TT variant occurs in approximately
10% of the population and results in 30% functional enzymatic
activity (Frosst et al., 1995; Lathrop Stern et al., 2000). The
MTHFR C677T polymorphism has not been identified in recent
genome-wide association studies as associated with susceptibil-
ity for prostate cancer (Thomas et al., 2008; Collin et al., 2009;
Kote-Jarai et al., 2011; Schumacher et al., 2011). However, it may
be relevant when examined in conjunction with folate and alco-
hol intakes to help explain prostate cancer risk not attributable to
susceptibility genes alone. Epidemiological studies have reported
associations between the TT variant genotype and reduced risks
of colorectal (Tiaoli et al., 2009) and breast (Qi et al., 2010)
cancers, while findings regarding prostate cancer conflict (Bai
et al., 2009; Collin et al., 2009; Cai et al., 2010). A simulation
study supports a role for folate-MTHFR genotype interaction in
carcinogenesis, showing reduced DNA methylation rates when
low MTHFR gene activity is combined with high intracellular
folate concentrations (Neuhouser et al., 2011). One epidemio-
logical study to date has considered this interaction in prostate
cancer, indicating an increased risk associated with high folate
intake among men with the TT MTHFR genotype (Van Guelpen
et al., 2006). To our knowledge, no previous study has exam-
ined the interaction between alcohol and MTHFR genotype in
prostate cancer etiology. We sought to assess the potential inde-
pendent and joint associations of folate intake, alcohol consump-




A case-control study was conducted where eligible men aged
50–80 years were recruited from Kingston General Hospital in
Kingston, ON, Canada from 1997 to 1999. Eligible participants
were either scheduled for prostate core biopsy or were visit-
ing the urology clinic for other reasons and had normal age-
specific prostate specific antigen (PSA) levels (≤3.5 in 50–60
age group, ≤4.5 in 60–70 age group, and ≤6.5 in 70–80 age
group) and a normal digital rectal examination (DRE). Of 1288
men seen in clinic, 746 did not meet these criteria. Of the 542
eligible subjects, 71 (13%) were excluded due to diagnosis of
prostate intraepithelial neoplasia, use of a hormonal medication,
or missing questionnaire, and 56 declined to participate (10%).
Participants were 414 men (76%) enrolled prior to knowledge
of diagnosis who completed a questionnaire regarding demo-
graphic, lifestyle, medical, diet and occupational histories, and
donated 15mL of blood. After biopsy and pathology exams for
214 eligible biopsy subjects, 80 were diagnosed as incident pri-
mary prostate cancer cases, and the other 134 were included
as “biopsy controls.” In addition, 200 eligible cancer-free men
of the same age distribution who were diagnosed with a non-
cancer urologic condition were enrolled as “urology controls,”
for a total of 334 controls. Among these groups, 43 cases (54%),
102 biopsy controls (76%), and 68 urology controls (34%) con-
sented to MTHFR genotype analysis. This study was approved
by the Human Ethics Research Board at Queen’s University and
Kingston General Hospital.
DIETARY NUTRIENT ASSESSMENT
The dietary section of the questionnaire was adapted from Byers
and colleagues’ food frequency questionnaire (Byers et al., 1985)
and requested information about intake of 62 food items in
the time period two years prior to interview. These food items
accounted for the majority of vitamin, fiber, fat, protein, and
caloric intakes, and the reproducibility and validity of a similar
questionnaire has been verified (Willett et al., 1988). Participants
were also asked about vitamin ormineral supplements containing
folate taken for six months or more. Results concerning prostate
cancer risk associated with dietary patterns and organochlo-
rine exposures were published previously (Walker et al., 2005;
Aronson et al., 2010).
Reported food intakes were converted to average consump-
tion per day and dietary nutrient levels were determined based
on the average portion size, as described in Canada’s Food
Guide. Folate was the primary nutrient of interest, while vita-
mins B2(riboflavin), B6, and B12, fat, energy, and methionine
levels were calculated due to their possible roles as confounding
factors. Specifically, food nutrient levels were determined using
the 1991 Canadian Nutrient file (Nutrition Research Division,
and Health Canada, 2001). Folic acid obtained from fortified
grain products was not included since mandatory fortification
did not start in Canada until 1998 and our data refer to prior
to that year. Calculations of methionine content were based on
the 2007 Canadian Nutrient file (Nutrition Research Division,
and Health Canada, 2007) since the 1991 version did not con-
tain these measurements. Data from the 2007 and 1991 Canadian
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Nutrient files were in agreement (excluding fortified grains) for
most categories.
For categories containing more than one food item (e.g.
“orange or grapefruit juice”), the Canada Food Statistics 1996
(Agriculture and Agri-Food Canada, and Statistics Canada, 2010)
and the Canadian Food Value Chain Bureau Retail Sales data
in 1996 (Agriculture and Agri-Food Canada, Food Value Chain
Bureau, 2004) were used to estimate the average consumption
of each food item within a food category (e.g., orange juice was
weighted as 93% and grapefruit juice as 7% of the total nutrient
value of “orange and grapefruit juice,” based on the average pur-
chases of each item). The unstable nature of folate when cooked
or heated was accounted for in the analysis since food prepara-
tion techniques impact nutrient levels. All components used to
determine the nutrient values for the 62 food items are available
upon request. Total nutrient levels were calculated for each indi-
vidual based on their average consumption, and nutrient levels
were adjusted to account for total caloric intake (Willett, 1998).
ALCOHOL CONSUMPTION ASSESSMENT
Alcohol consumption was defined as one alcoholic drink = 12
oz of beer, 4 oz of wine, or 1.5 oz of liquor. Alcohol exposure
variables were: age started drinking, years drinking, average total
alcohol per week two years prior to study entry, average weekly
consumption of beer, wine, and liquor separately two years prior
to study entry, and lifetime alcohol intake.
MTHFR C677T POLYMORPHISM ANALYSIS
Blood samples were stored at –80◦C and were defrosted
to room temperature for analysis. DNA isolation was per-
formed using the QIAamp DNA Blood Mini Kit spin protocol
(Qiagen, Valencia, CA), and PCR-RFLP analysis was based
on methods described previously (Frosst et al., 1995; El-
Sammak et al., 2004). Primers corresponding to the C677T
site of the MTHFR gene had the exonic sequence of 5′-
TGAAGGAGAAGGTGTCTGCGGGA-3′ and the intronic
sequence of 5′-AGGACGGTGCGGTGAGAGTG-3′. The MTHFR
C667T polymorphism was identified using the HinfI enzyme
(Promega), which cleaves the DNA when the variant allele is
present. The wildtype CC fragment showed a 198 base pair (bp)
fragment when analysed by gel electrophoresis. The cleaved
homozygous TT variant showed two fragments of 175 and 23 bp.
The cleaved heterozygous CT variant produced three fragments
of 198, 175, and 23 bp. To ensure quality control, PCR-RFLP
results for a subset of gene fragments were verified against exact
nucleotide sequences for these fragments, as sequenced by Cortec
DNA Service Laboratories (Kingston, ON).
STATISTICAL ANALYSIS
Independent associations between folate intake, alcohol con-
sumption, and MTHFR C677T genotype and risk of prostate
cancer were estimated using unconditional logistic regression,
with age included in all models. Folate intake was adjusted for
energy intake, and was analysed continuously (per 100μg/day),
as tertiles based on intake among controls, and as ever use of a
vitamin or mineral supplement containing folate for ≥6 months
(yes/no). Intakes of vitamins B2, B6, and B12, and methionine
were each analysed in these ways. Folate intake was also examined
by Gleason score among cases, stratified into highly (score ≥7)
and less aggressive (score 5–6) groups. Alcohol consumption was
analysed as age started drinking, total alcohol intake per week
(>5 drinks vs. ≤5), total beer, wine, and liquor per week (1–7
drinks and ≥8 drinks vs. <1 drink), and total lifetime alco-
hol intake (continuous per 1000 drinks, and as tertiles based
on distribution among controls). Analyses of alcohol variables
were performed excluding never drinkers (n = 68 cases and 292
controls included). MTHFR genotype was analysed with risk of
the CT (heterozygous mutant) and TT genotypes (homozygous
mutant) compared with the CC genotype (wildtype), both indi-
vidually and combined as CT + TT in a dominant genetic model
(Lewis, 2002). Potential confounders in addition to age were
selected using a backward change-in-estimate (≥10%) method
(Rothman and Greenland, 1998).
The joint effects of folate intake, alcohol consumption, and
MTHFR genotype were estimated using unconditional logistic
regression models adjusted for the same covariates as the main
effect models, with combinations of low folate intake, low alco-
hol consumption, and the CC MTHFR genotype as the com-
mon reference groups. Low folate consumption was defined as
≤214.03μg per day (with>214.03 defined as high), and low alco-
hol consumption was defined as ≤5 drinks per week (with >5
defined as high). Statistical significance of multiplicative and
additive interactions was assessed from the likelihood ratio tests
performed using the GENMOD procedure in SAS, which allows
testing of these two types of interactions separately in general
linear models (Littell et al., 2002). Analyses of interactions involv-
ing MTHFR genotype were performed using a dominant genetic
model where the CT and TT genotypes were combined and
compared to the CC genotype, as too few cases and controls dis-
played the TT genotype to use an additive gene model (Lewis,
2002).
Sensitivity analyses compared cases to a sub-group of controls
excluding biopsy controls, and separately to controls excluding
those with benign prostatic hyperplasia. Statistical analyses were
performed using SAS (Version 9.2, SAS Institute, Cary, NC).
RESULTS
While most characteristics of cases and controls were similar
(Table 1), controls had more cumulative smoking exposure and
cases were more likely than controls to report strenuous physi-
cal activity as a teen. In terms of the exposures of interest, cases
started drinking alcohol at a younger mean age (18 years old) than
controls (almost 20 years old), and consumed more total alco-
hol per week on average than controls (Table 2). Consumption
of folate was similar between cases and controls (Table 2).
Consumption of vitamins B2, B6, B12, andmethionine was similar
(not shown).
No association with prostate cancer risk was apparent for
dietary folate analysed continuously, by tertile, or according sup-
plement use as the source, nor for vitamins B2, B6, B12, or
methionine (folate only shown inTable 2). When cases were strat-
ified by Gleason score, 57% had a score ≥7, and 43% had a
score 5–6. Of those with Gleason score ≥7, 32% were in the low-
est tertile of folate intake, while 12% with a score of 5–6 were
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Table 1 | Characteristics of study participants, n = 414 (80 cases; 334
controls).
Characteristics Cases n (%) Controls n (%) p-value
Age (years), mean
± SD
65.1 ± 6.0 63.6 ± 6.9 0.08
GLEASON SCORE
5 3 (4) − −
6 30 (38) − −
7 25 (31) − −
8 11 (14) − −
9 8 (10) − −
Missing 3 (4) − −
MARITAL STATUS
Married 73 (91) 286 (86) 0.18
Other 7 (9) 48 (14) −
ANCESTRY
British 59 (74) 230 (70) 0.48
Other 21 (26) 100 (30) −
EDUCATION
Secondary or less 39 (49) 160 (48) 0.91
Post- secondary 41 (51) 173 (52) −
PERSONAL INCOME
Low 43 (54) 190 (57) 0.61
High 37 (46) 144 (43) −
BMI AT AGE 40 YEARS (kg/m2)
Mean ± SD 24.5 ± 0.3 25.0 ± 3.1 0.28
<23.68 29 (36) 113 (33) 0.64∗
23.69–25.88 29 (36) 111 (33) −
>25.88 22 (28) 110 (33) −
CURRENT SMOKING STATUS
No 65 (81) 293 (88) 0.13





30.6 ± 1.7 43.0 ± 6.1 0.06
FIRST-DEGREE FAMILY HISTORY OF PROSTATE CANCER
No 61 (86) 270 (85) 0.87
Yes 10 (14) 47 (15) −
FIRST-DEGREE FAMILY BREAST CANCER HISTORY
No 70 (91) 279 (87) 0.40
Yes 7 (9) 40 (13) −
PHYSICAL ACTIVITY AS A TEEN
Little 20 (25) 133 (40) 0.012
Moderate 39 (49) 150 (45) −
Strenuous 21 (26) 50 (15) −
VASECTOMY
No 58 (72.5) 240 (72) 0.90
Yes 22 (27.5) 94 (28) −
∗p for trend.
p-values < 0.05 were considered statistically significant.
in the lowest tertile, indicating lower folate with more prostate
cancer progression (p-trend = 0.06).
In terms of alcohol consumption, also seen in Table 2, the
highest tertile of lifetime total alcohol intake was associated with a
doubling in prostate cancer risk (OR = 2.08; 95% CI: 1.12–3.86).
Average weekly total alcohol consumption of greater than five
drinks per week was associated with increased prostate cancer risk
(OR= 1.75; 95% CI: 1.00–3.06).When further adjusted for folate
intake, MTHFR C677T genotype, and the multiplicative inter-
action between the two, the magnitude of risk was even higher
(OR = 3.22; 95% CI: 1.36–7.59).
In terms ofMTHFR C677T genotype among consenting cases,
44% displayed the CT genotype, 5% displayed the TT genotype,
and 51% displayed with wildtype CC genotype. Among geno-
typed controls, these numbers were 51, 7, and 42%, respectively.
The CT and TT MTHFR genotypes were not associated with
prostate cancer risk (Table 2).
Folate intake and alcohol consumption considered together are
shown in Table 3. Combined high alcohol and low folate intakes
were associated with increased prostate cancer risk (OR = 2.38;
95% CI: 1.01–5.57), although the interaction was not significant
under multiplicative or additive models (Table 3). No multiplica-
tive or additive effects ofMTHFR genotype and folate intake were
observed (Table 4). When theMTHFR genotype and alcohol con-
sumption were investigated together, the OR for >5 compared
to ≤5 drinks per week was 4.43 (95% CI: 1.15–17.05) within the
CC genotype (Table 5). Sensitivity analyses comparing cases to
controls excluding biopsy controls, and separately to controls not
diagnosed with benign prostatic hyperplasia, found results similar
to the overall analysis.
DISCUSSION
In this study of incident primary prostate cancer cases and clinic-
based controls, all of whom were men with normal PSA and
DRE results, independent effects of folate intake and MTHFR
genotype on prostate cancer risk were not observed. We did
observe that total lifetime alcohol consumption increased prostate
cancer risk two-fold among men in the highest consumption
tertile. Further, consumption of more than five alcoholic drinks
per week increased prostate risk over two-fold among men with
low folate intake and over four-fold among men with the CC
genotype. Average weekly alcohol consumption was also asso-
ciated with increased prostate cancer risk when folate intake,
MTHFR C677T genotype, and their multiplicative interaction
were accounted for. We observed no gene-environment inter-
action between the MTHFR C677T polymorphism and folate
intake.
Our findings for the effects of folate intake on prostate can-
cer risk are consistent with five case-control studies (Vlajinac
et al., 1997; Weinstein et al., 2003; Johansson et al., 2008;
Zhang et al., 2009; Collin et al., 2010b) and three cohort stud-
ies (Stevens et al., 2006; Weinstein et al., 2006; Beilby et al.,
2010). Our results are inconsistent with two case-control stud-
ies reporting decreased risk with higher dietary folate intake
(Pelucchi et al., 2005; Shannon et al., 2009), and a prospec-
tive study and randomized clinical trial both finding increased
risk with higher intakes (Hultdin et al., 2005; Figueiredo et al.,
2009). Inconsistent findings from existing studies may be in part
due to failure to take interactions and stage and/or grade of
prostate cancer at diagnosis into account. Increasing evidence
supports a dual role for folate intake in prostate carcinogenesis
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Table 2 | Associations between folate intake, alcohol consumption, the MTHFR C677T polymorphism, and prostate cancer risk, n = 414 (80
cases; 334 controls).
Cases n (%) Controls n (%) OR (95% CI)
FOLATE INTAKE∗
Folate(μg/day)
Continuous (per 100μg/day mean ± SD) 217.9 ± 5.7 220.6 ± 2.9 0.78 (0.47–1.30)
Tertiles
≤197.54 26 (33) 111 (33.3) 1.00 (ref)
>197.54<234.99 25 (31) 112 (33.3) 0.85 (0.45–1.62)
≥234.99 29 (36) 111 (33.3) 1.03 (0.55–1.95)
Supplement containing folate
<6 months 50 (62.5) 217 (65) 1.00 (ref)
≥6 months 30 (37.5) 117 (35) 1.15 (0.67–1.97)
ALCOHOL CONSUMPTION§
Age starting drinking (per 1 year; mean ± SD) 18.5 ± 4.6 19.9 ± 6.9 0.95 (0.90–1.00)
Total years drinking (per 10 years; mean ± SD) 41.9 ± 12.5 41.2 ± 12.5 0.96 (0.83–1.10)
Total alcohol intake per week
Adjusted for age
≤5 drinks 22 (32) 133 (46) 1.00 (ref)
>5 drinks 46 (68) 159 (54) 1.75(1.00–3.06)
Adjusted for age, folate, MTHFR C677T genotype,
and multiplicative folate-genotype interaction
≤5 drinks 8 (22) 68 (47) 1.00 (ref)
>5 drinks 29 (78) 78 (53) 3.22 (1.36–7.59)
Beer intake per week
<1 drink 30 (44) 147 (50) 1.00 (ref)
1–7 drinks 27 (40) 111 (38) 1.23 (0.69–2.21)
≥8 drinks 11 (16) 34 (12) 1.69 (0.76–3.72)
Wine intake per week
<1 drink 35 (51) 157 (54) 1.00 (ref)
1–7 drinks 24 (35) 112 (38) 0.95 (0.54–1.69)
≥8 drinks 9 (13) 23 (8) 1.71 (0.73–4.04)
Liquor intake per week
<1 drinks 35 (52) 173 (59) 1.00 (ref)
1–7 drinks 25 (37) 103 (35) 1.21 (0.69–2.14)
≥8 drinks 8 (12) 16 (6) 2.27 (0.89–5.80)
Total lifetime alcohol intake
Continuous (per 1000 drinks) 296.6 ± 166.9 176.1 ± 178.9 1.01 (1.00–1.03)
Tertiles
Low 10 (19) 71 (33) 1.00 (ref)
Middle 16 (30) 72 (33) 1.31 (0.66–2.60)
High 27 (51) 73 (34) 2.08 (1.12–3.86)
MTHFR C677T POLYMORPHISM§
CC 22 (51) 72 (42) 1.00 (ref)
CT 19 (44) 86 (51) 0.72 (0.36–1.44)
TT 2 (5) 12 (7) 0.55 (0.11–2.65)
CT + TT vs. CC 21 (49) 98 (58) 0.70 (0.36–1.37)
∗ORs adjusted for age, personal income, marital status, physical activity as a teen, family history of breast cancer.
§ORs adjusted for age.
p-values < 0.05 were considered statistically significant.
wherein both high and low intakes may have deleterious effects
at different stages in tumor progression (Stevens et al., 2006;
Shannon et al., 2009; Collin et al., 2010a,b; Bistulfi et al.,
2011).
The distribution of MTHFR genotypes among both cases and
controls in our study was similar to the estimated population
distribution of approximately 40, 50, and 10% prevalence for the
CC, CT, and TT genotypes, respectively (Lathrop Stern et al.,
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Table 3 | Folate intake, alcohol consumption, and prostate cancer risk
(68 cases; 292 controls).
Folate Alcohol Cases Controls OR (95% CI)∗
intake consumption n (%) n (%)
Low Low 10 (15) 68 (23) 1.00 (ref)
Low High 26 (38) 76 (26) 2.38 (1.01–5.57)
High Low 12 (18) 65 (22) 1.16 (0.44–3.09)
High High 20 (29) 83 (28) 1.67 (0.70–4.01)
p-interaction (multiplicative) 0.80
p-interaction (additive) 0.69
∗ORs adjusted for age, personal income, marital status, physical activity as a
teen, and family history of breast cancer.
p-values < 0.05 were considered statistically significant.
Table 4 | Folate intake,MTHFR C677T genotype, and prostate cancer
risk (43 cases, 170 controls).
Folate MTHFR Cases Controls OR (95% CI)∗
intake genotype n (%) n (%)
Low CC 11 (26) 33 (19) 1.00 (ref)
Low CT + TT 11 (26) 47 (28) 0.85 (0.31–2.37)
High CC 11 (26) 39 (23) 1.06 (0.37–3.03)
High CT + TT 10 (23) 51 (30) 0.73 (0.26–2.08)
p-interaction (multiplicative) 0.73
p-interaction (additive) 0.76
∗ORs adjusted for age, personal income, marital status, physical activity as a
teen and family history of breast cancer.
Table 5 | Alcohol consumption, MTHFR C677T genotype, and prostate
cancer risk (37 cases; 146 controls).
Alcohol MTHFR Cases Controls Age-adjusted
consumption genotype n (%) n (%) OR (95% CI)
Low CC 3 (8) 29 (20) 1.00 (ref)
Low CT + TT 5 (14) 39 (27) 1.25 (0.28–5.65)
High CC 14 (38) 31 (21) 4.43 (1.15–17.05)
High CT + TT 15 (41) 47 (32) 3.10 (0.83–11.65)
p-interaction (multiplicative) 0.51
p-interaction (additive) 0.58
p-values < 0.05 were considered statistically significant.
2000). Our results for the CT and TT MTHFR genotypes were
null, although the ORs below one that we observed are consis-
tent with onemeta-analysis (Bai et al., 2009), while another shows
no association between the MTHFR C677T polymorphism and
prostate cancer risk (Collin et al., 2009).
Although this is a relatively small study that lacked power to
detect most interactions, our finding of an over two-fold increase
in prostate cancer risk for the interaction of low folate and high
alcohol intake is consistent biologically with prostate carcinogen-
esis resulting from folate deficiency (Bistulfi et al., 2010). Other
epidemiologic evidence for a folate-alcohol interaction is conflict-
ing (Weinstein et al., 2003; Pelucchi et al., 2005; Stevens et al.,
2006; Shannon et al., 2009). One study has examined a MTHFR-
folate genotype interaction in prostate cancer, finding that the
C677T polymorphism increases risk at high plasma folate lev-
els (Van Guelpen et al., 2006). Our finding of an over four-fold
increase in prostate cancer risk associated with alcohol consump-
tion among men with the CC MTHFR genotype indicates a
potentially strong gene-environment interaction between these
two factors that has not been investigated in any other study we
are aware of.
Strengths of this study include rigorous exclusion criteria
and confirmation of all controls as having normal age-specific
PSA levels. This decreased selection bias and ensured that the
control group was not contaminated with latent prostate can-
cer. All men visited the same urologists in a single hospital
and resided in the same geographic catchment area. Because
all participants were recruited and completed the questionnaire
prior to knowledge of disease status, differential recall error, and
interviewer bias were avoided in this study. The food frequency
questionnaire was highly detailed, reproducible, and valid, and
was designed to represent average diet two years prior to study
enrollment. The comprehensive statistical analysis of folate, B
vitamins, and methionine, using energy-adjustment and three
types of input variables also reduced the possibility of exposure
misclassification. Questioning about average alcohol intake two
years prior (relatively recent) reduced the possibility of recall error
(Middleton Fillmore et al., 2009), and the comprehensive indica-
tors of alcohol consumption reduced the possibility of exposure
misclassification.
Dietary folate consumption among our study population was
measured prior to 1998, when folate fortification of white wheat
flour becamemandatory in Canada and the United States. Dietary
folate consumption and folate status of our study population are
likely lower than that of the more recent general Canadian and
US populations (Baily et al., 2010; Colapinto et al., 2011). Our
results are relevant since assessing lower folate consumption in
these countries may bemore difficult now because of fortification.
However, low variation in our observed range of folate intakes
may have limited our ability to detect both main effects and inter-
actions with folate, since folate intake in the first and third tertiles
differed by only 38μg in our study.
In summary, we found that alcohol consumption is associ-
ated with increased prostate cancer risk, with higher risk among
men with low folate intake and among men with the CCMTHFR
genotype. Taking into account potential combined effects and
interactions is important for future studies, and may in part
explain inconsistent findings to date. Future work should also
capture a greater range of folate intakes to determine the true
role of folate in prostate carcinogenesis, and whether this is role
is dualistic in nature, to inform public policy regarding folate
fortification.
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